Trimethaphan
Ganglionic blockade, now largely of historical interest, is the mechanism of trimethaphan: the agent competitively antagonises nicotinic acetylcholine receptors at both sympathetic and parasympathetic ganglia. Interrupting autonomic outflow at the ganglion produces rapid and controllable hypotension, and the effect ends quickly once infusion stops. Those properties suited it to deliberate hypotension during surgery and to hypertensive emergencies, aortic dissection in particular, where blood pressure had to be lowered precisely and reversibly by intravenous infusion. Blocking both autonomic divisions simultaneously also produces the parasympathetic effects characteristic of the class. The compound is recorded as C22H25N2OS with a mass near 365.5 g/mol.
Trimethaphan is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at both sympathetic and parasympathetic ganglia, producing rapid and controllable hypotension. It was used for controlled hypotension during surgery and for the management of hypertensive emergencies, particularly aortic dissection. Its short duration of action allowed for precise blood pressure control via intravenous infusion.
Peso molecular
365,5000 g/mol
LogP
3,60
TPSA
24,60 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Estructura 2D
Cite this structure
Embed this structure
SMILES
O=C1N(Cc2ccccc2)C2C[S+]3CCCC3C2N1Cc1ccccc1
InChI
InChI=1S/C22H25N2OS/c25-22-23(14-17-8-3-1-4-9-17)19-16-26-13-7-12-20(26)21(19)24(22)15-18-10-5-2-6-11-18/h1-6,8-11,19-21H,7,12-16H2/q+1
Molecular Formula
C22H25N2OS+
HBD / HBA
- / 1
Enlaces Rotables
4
Átomos Pesados
26
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
Trimethaphan is a ganglionic blocking agent that competitively antagonizes nicotinic acetylcholine receptors at both sympathetic and parasympathetic ganglia, producing rapid and controllable hypotension. It was used for controlled hypotension during surgery and for the management of hypertensive emergencies, particularly aortic dissection. Its short duration of action allowed for precise blood pressure control via intravenous infusion.
Yes, Trimethaphan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201329. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 23576. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="trimethaphan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/trimethaphan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/trimethaphan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/trimethaphan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="trimethaphan"></drugfyi-drug>